← All Lipella Pharmaceuticals INC filings

Lipella Pharmaceuticals INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

OTC.Pink
LIPO
Lipella Pharmaceuticals INC
DEFA14A: Lipella Pharmaceuticals Adjourns Special Stockholder Meeting Due to Lack of Quorum
Lipella Pharmaceuticals adjourned its special stockholder meeting on December 20, 2024, due to the absence of a quorum and will reconvene on December 27, 2024.
OTC.Pink
LIPO
Lipella Pharmaceuticals INC
DEFA14A: Lipella Pharmaceuticals Special Meeting Adjourned Due to Lack of Quorum
Lipella Pharmaceuticals' special meeting of stockholders was adjourned due to a lack of quorum and will reconvene on December 20, 2024.
OTC.Pink
LIPO
Lipella Pharmaceuticals INC
DEF 14A: Lipella Pharmaceuticals Seeks Stockholder Approval for Equity Line of Credit Transaction
Lipella Pharmaceuticals is seeking stockholder approval to issue 20% or more of its common stock to secure an equity line of credit, aiming to regain compliance with Nasdaq's minimum equity requirement.
OTC.Pink
LIPO
Lipella Pharmaceuticals INC
DEF 14A: Lipella Pharmaceuticals Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing
Lipella Pharmaceuticals is asking stockholders to approve a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and potentially improve stock marketability.